INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 55 filers reported holding INOZYME PHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,370 | -50.0% | 7,469 | -33.7% | 0.00% | – |
| Q2 2023 | $62,718 | +150.9% | 11,260 | +87.8% | 0.00% | – |
| Q1 2022 | $25,000 | -52.8% | 5,996 | -22.4% | 0.00% | – |
| Q4 2021 | $53,000 | -41.1% | 7,730 | 0.0% | 0.00% | – |
| Q3 2021 | $90,000 | -73.5% | 7,730 | -61.1% | 0.00% | – |
| Q2 2021 | $339,000 | -5.6% | 19,867 | +9.5% | 0.00% | – |
| Q1 2021 | $359,000 | +41.3% | 18,143 | +47.5% | 0.00% | – |
| Q4 2020 | $254,000 | -21.4% | 12,298 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $323,000 | – | 12,298 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |